Vantictumab, formerly labeled as OMP18R5, represents a novel targeted agent designed with specifically block bone associated molecule 18R5. This therapy is being developed by the company regarding anticipated treatments in various orthopedic diseases, particularly those involving abnormal osseous breakdown. Preclinical findings suggest that can sig